First line treatment of metastatic renal cell carcinoma
نویسندگان
چکیده
منابع مشابه
Economic evaluation of sunitinib malate for the first-line treatment of metastatic renal cell carcinoma.
PURPOSE To assess the cost effectiveness and cost utility of sunitinib malate as a first-line treatment in metastatic renal cell carcinoma (mRCC) compared with interferon-alfa (IFN-alpha) and interleukin-2 (IL-2) from a US societal perspective. METHODS A Markov model was developed to simulate disease progression and to determine progression-free survival, total life-years (LYs), and quality-a...
متن کاملMetastatic Renal Cell Carcinoma: Sunitinib as First-Line Treatment; Results of a Retrospective Study
In adults, renal cell carcinoma (RCC) is the most common type of kidney cancer, responsible for 90–95% of cases and the predominant pathology is clear cell carcinoma [1]. About 25–30% of cases are metastatic at the time of diagnosis [2]. As RCC is highly resistant to chemotherapy, immunotherapeutic agents such as interleukin 2 and interferon alpha (IFN-α) were the only available first-line trea...
متن کاملIs PazOPaNIb the Preferred fIrst-LINe treatmeNt fOr metastatIc reNaL ceLL carcINOma?
CoMMEntARy: Highlights of the 8 Annual Meeting of the Canadian Association of Genitourinary Medical Oncologists included a debate between Dr. Kylea Potvin from the London Health Sciences Centre and Dr. Piotr Czaykowski of CancerCare Manitoba in Winnipeg on the optimal treatment for metastatic renal cell carcinoma. Sunitinib is an oral small molecule multikinase inhibitor considered the de facto...
متن کاملDyspnea as the First Manifestation of Silent Renal Cell Carcinoma
Renal cell carcinoma (RCC) accounts for only 3% of adult malignancies, and the lung is the most common site of metastasis of this tumor, which may be accompanied by pleural metastasis. However, solitary pleural involvement is very rare and its presentation with dyspnea as the first manifestation of RCC is extremely rare.We describe a 39-year-old male with episodes of dyspnea dating back 6...
متن کاملContemporary Treatment of Metastatic Renal Cell Carcinoma
The introduction of targeted therapy has revolutionized the treatment of patients with metastatic renal cell carcinoma (mRCC). The current standard of care focuses on the inhibition of angiogenesis through the targeting of the vascular endothelial growth factor receptor (VEGFR) and the mammalian target of rapamycin (mTOR). Over the past few years, research exploring novel targeted agents has bl...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Cancer Biology & Therapy
سال: 2013
ISSN: 1538-4047,1555-8576
DOI: 10.4161/cbt.27150